Scarica l'app Stockscreener
27.91
0.92%
-0.26
Dopo l'orario di chiusura:
27.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CSTL Giù?
Forum
Previsione
Castle Biosciences Inc Borsa (CSTL) Ultime notizie
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - The Manila Times
Castle Biosciences to Present Data at SSO 2026 on - GlobeNewswire
Castle Biosciences (NASDAQ:CSTL) Lowered to Hold Rating by Zacks Research - MarketBeat
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Bitget
CSTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Canaccord reiterates Castle Biosciences stock rating on Q4 beat By Investing.com - Investing.com India
Canaccord reiterates Castle Biosciences stock rating on Q4 beat - Investing.com
Aug Volume: What is the target price for Seer Inc stockEarnings Beat & Community Shared Stock Ideas - baoquankhu1.vn
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling a Promising 50.96% Upside for Investors - DirectorsTalk Interviews
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownWhat's Next? - MarketBeat
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - Finviz
Castle Biosciences (CSTL) Analyst Rating Update: Baird Raises Pr - GuruFocus
Robert W. Baird Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Expert Outlook: Castle Biosciences Through The Eyes Of 6 Analysts - Benzinga
Castle Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-02-27 - Seeking Alpha
Castle Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Transcript : Castle Biosciences, Inc., Q4 2025 Earnings Call, Feb 26, 2026 - marketscreener.com
Volatility Watch: Will Castle Biosciences Inc stock go up in YEAR2025 Bull vs Bear & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results - MarketBeat
Castle Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Castle Biosciences Q4 2025 slides: test volumes surge 42%, enters AD market - Investing.com
Castle Biosciences (CSTL) Earnings Transcript - AOL.com
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Castle Biosciences Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Castle Biosciences Q4 2025 beats expectations, stock rises - Investing.com
Earnings Flash (CSTL) Castle Biosciences, Inc. Reports Q4 Revenue $87.0M, vs. FactSet Est of $79.9M - marketscreener.com
Castle Biosciences Posts Modest 2025 Growth Amid Headwinds - TipRanks
Earnings Flash (CSTL) Castle Biosciences, Inc. Posts Q4 Adjusted Loss $0.08 per Share, vs. FactSet Est of $-0.26 - marketscreener.com
Castle Biosciences Reports 37% Increase in Core Test Reports for 2025, Achieving $344 Million in Revenue - Quiver Quantitative
Castle Biosciences (CSTL) swings to 2025 loss as margins compress - Stock Titan
Skin cancer test maker lifts core volumes 37%, ends 2025 with $24.2M loss - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Castle Biosciences Stock Hits Day Low of $27.80 Amid Price Pressure - Markets Mojo
Exploring Castle Biosciences's Earnings Expectations - Benzinga
RTW INVESTMENTS, LP Acquires Significant Stake in Castle Bioscie - GuruFocus
Castle Biosciences, Inc. (CSTL) Stock Report: Analysts See 54.98% Potential Upside Amidst Innovative Diagnostics - DirectorsTalk Interviews
Castle Biosciences Publishes Study Demonstrating AdvanceAD-Tx Test Improves Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis Patients - Quiver Quantitative
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis - The Manila Times
New skin test steers severe eczema patients to faster JAK drug relief - Stock Titan
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 7%Should You Sell? - MarketBeat
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
Castle Biosciences (CSTL) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis - Bitget
Can Castle Biosciences Inc. maintain its current growth rateRecession Risk & Precise Trade Entry Recommendations - mfd.ru
RTW Investments reveals 7.2% Castle Biosciences (CSTL) stake in 13G filing - Stock Titan
How do insiders feel about Castle Biosciences Inc2025 Market Outlook & Verified High Yield Trade Plans - baoquankhu1.vn
Aug Weekly: Why is CKPT stock going upJuly 2025 Action & Daily Entry Point Trade Alerts - baoquankhu1.vn
Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 52% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Castle Biosciences (CSTL) loses 16.8% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Castle Biosciences stock jumps after FDA grants Breakthrough Device status to melanoma test - MSN
EV Market: Can Castle Biosciences Inc deliver alpha2025 Stock Rankings & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Aug Weekly: Can Castle Biosciences Inc. maintain its current growth rateEarnings Overview Report & Long-Term Investment Growth Plans - baoquankhu1.vn
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
Castle Biosciences, Inc. $CSTL Shares Sold by Allianz Asset Management GmbH - MarketBeat
Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 49.91% Upside Potential for Investors - DirectorsTalk Interviews
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,200 Shares of Stock - MarketBeat
Derek Maetzold Sells 817 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
What Catalysts Are Rewriting The Castle Biosciences (CSTL) Story For Wall Street Analysts - Yahoo Finance
2.14%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):